Biohaven
BHVN · NYSE · United States
Share price · BHVN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BHVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026+25.0%
- 17 Sep 2026+15.6%
Nothing announced by BHVN that day or the session before.
- 10 Sep 2026-14.7%
- 26 Aug 2026+17.9%
- 22 Jun 2026+14.2%
Nothing announced by BHVN that day or the session before.
- 17 Jun 2026+12.7%
Nothing announced by BHVN that day or the session before.
- 28 May 2026-9.3%
- 27 May 2026+12.1%
- 11 May 2026-7.9%
Nothing announced by BHVN that day or the session before.
- 17 Apr 2026+9.7%
Nothing announced by BHVN that day or the session before.
Share of unusual movement by asset
For each asset, the share of BHVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Gd-IgA1 (galactose-deficient IgA1)Biologic (subtype unspecified) | Chronic Kidney Disease | |
| Phase 3 | Activin/myostatin type II receptorAntibody-derived scaffold | ObesitySpinal Muscular Atrophy | |
| Phase 3 | Glutamate transporters (EAAT)Small molecule | Spinocerebellar Ataxia | |
| Phase 2/3 | TYK2/JAK1Small molecule | Parkinson's Disease | |
| Phase 2/3 | Kv7 potassium channelSmall molecule | Epilepsy Focal Onset Seizures | |
| Phase 2 | TRPM3 | Migraine | |
PBI-100No recent activity | Phase 1 | TrkASmall molecule | Psoriasis |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (1)
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $102M | $99M+ $65M short-term inv. | $129M-$107M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $101M | $241M+ $30M short-term inv. | $137M-$85M operating cash flow | report ↗ |
| 2026-Q1 | — | $104M | $277M+ $75M short-term inv. | $131M-$150M operating cash flow | report ↗ |
| 2025-Q3 | — | $141M | $188M+ $75M short-term inv. | $173M-$146M operating cash flow | report ↗ |
| 2025-Q2 | — | $184M | $169M+ $239M short-term inv. | $198M-$168M operating cash flow | report ↗ |
| 2025-Q1 | — | $188M | $103M+ $224M short-term inv. | $222M-$165M operating cash flow | report ↗ |
| 2024-Q3 | — | $158M | $88M+ $294M short-term inv. | $160M-$141M operating cash flow | report ↗ |
| 2024-Q2 | — | $315M | $242M+ $198M short-term inv. | $320M-$168M operating cash flow | report ↗ |
| 2024-Q1 | — | $156M | $187M+ $101M short-term inv. | $180M-$103M operating cash flow | report ↗ |
| 2023-Q3 | — | $96M | $126M+ $129M short-term inv. | $103M-$95M operating cash flow | report ↗ |
| 2023-Q2 | — | $79M | $202M+ $188M short-term inv. | $90M-$44M operating cash flow | report ↗ |
| 2023-Q1 | — | $63M | $191M+ $263M short-term inv. | $70M-$78M operating cash flow | report ↗ |
| 2022-Q3 | — | $53M | $51M | $69M-$96M operating cash flow | report ↗ |
| 2022-Q2 | — | $177M | $24M | $203M-$68M operating cash flow | report ↗ |
| 2022-Q1 | — | $70M | $41M | $97M-$59M operating cash flow | report ↗ |
| 2021-Q3 | — | $47M | $363M | $54M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $635M | $233M+ $89M short-term inv. | $185M-$609M operating cash flow | report ↗ |
Biohaven reported no revenue disclosure for FY2025, with R&D spend of $635.07M, down 20.2% YoY from $795.87M. Cash and equivalents were $232.78M, and the company reported a net loss of $738.82M, with a stated quarterly net burn of $738.82M; total cash, cash equivalents, marketable securities and restricted cash approximated $322.0M as of December 31, 2025.
The company is prioritizing three late-stage programs: extracellular protein degraders for immunology, Kv7 modulation for epilepsy, and myostatin-activin targeting for obesity. BHV-1300 showed IgG reductions up to 87% and is planned for a pivotal Graves’ disease study in 2H 2026; BHV-1400 achieved early biomarker and clinical responses in IgAN, with a pivotal study expected to initiate in 1Q 2026; opakalim’s open-label extension showed 50% or greater seizure frequency reductions in most participants completing six months, with pivotal topline results expected in 2H 2026; and taldefgrobep alfa’s Phase 2 obesity trial topline is expected in 2H 2026. Biohaven also initiated a 4Q 2025 restructuring expected to cut annual direct R&D spend by approximately 60%, and subsequently raised $178.9M in net proceeds from a common share sale.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $796M | $103M+ $387M short-term inv. | $212M-$582M operating cash flow | report ↗ |
| 2023-FY | — | $373M | $252M+ $133M short-term inv. | $102M-$332M operating cash flow | report ↗ |
| 2022-FY | — | $437M | $243M+ $260M short-term inv. | $143M-$298M operating cash flow | report ↗ |
| 2021-FY | — | $181M | $77M+ $0 short-term inv. | $53M-$146M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-15 | Gentile Kimberly · SVP, Clinical Operations | Award / grant (derivative) | 1,000 | — | — | Form 4 |
| 2026-04-28 | GREGORY JULIA P · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | HUGIN ROBERT J · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | CHILDS JOHN W · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | Antonijevic Irina · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | Heffernan Michael Thomas · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | Bailey Gregory · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
| 2026-04-28 | Mehta Kishan · director | Award / grant (derivative) | 68,693 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 273 reporting institutions held 143.6M shares ($1.2B, 95.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 17,534,612 | $148.2M |
| 2 | BlackRock, Inc. | 11,222,407 | $94.9M |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 10,286,937 | $87.0M |
| 4 | STIFEL FINANCIAL CORP | 9,940,885 | $84.1M |
| 5 | STATE STREET CORP | 6,618,803 | $56.0M |
| 6 | INFINITUM ASSET MANAGEMENT, LLC | 6,250,000 | $52.9M |
| 7 | TCG Crossover Management, LLC | 4,631,317 | $39.2M |
| 8 | STEMPOINT CAPITAL LP | 3,188,982 | $27.0M |
| 9 | Royalty Pharma Sub-Manager, LLC | 2,936,507 | $24.8M |
| 10 | D. E. Shaw & Co., Inc. | 2,847,193 | $24.1M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2,767,763 | $23.4M |
| 12 | GOLDMAN SACHS GROUP INC | 2,513,181 | $21.3M |
| 13 | Balyasny Asset Management L.P. | 2,445,416 | $20.7M |
| 14 | FMR LLC | 2,359,047 | $20.0M |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,279,275 | $19.3M |